Episomal Vector Design for Universal Mammalian Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protein production systems, particularly for biologics, face inefficiencies and high costs due to the need for multiple cloning steps and vector backbones, which complicates the production of both small and large-scale cell cultures, and introduces phenotypic changes when vectors integrate into the host genome.
Innovation Solution
The development of episomal vectors equipped with two different origins of replication, such as OriP from Epstein-Barr virus and SV40, allows for universal use across various mammalian cell lines without the need for re-cloning, utilizing either a cloned replication initiation factor or one expressed by the host cell, thereby reducing cloning steps and maintaining high protein production levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple different episomal vector backbones are used for different cell lines, then protein production can be achieved in various cell types, but the cloning process becomes complex and time-consuming
Solution Approach 1:
The patent creates a universal episomal vector backbone that can function in multiple cell lines by incorporating both SV40 and EBV origins of replication. This single vector design replaces the need for multiple cell-line-specific vectors, allowing one vector to serve multiple functions across different mammalian cell types expressing either SV40 TAg or EBNA-1
Solution Approach 2:
The patent merges two previously separate vector systems (SV40-based and EBV-based episomal vectors) into a single hybrid vector containing both origins of replication. This combination allows the vector to replicate and maintain itself in cell lines expressing either SV40 TAg or EBNA-1, eliminating the need to choose between different vector backbones
2Stability of the object's composition
If vectors integrate into the host genome, then stable maintenance is achieved, but phenotypic changes occur in the cell
Solution Approach 1:
The patent uses episomal replication to maintain the vector as a separate, independent circular DNA molecule rather than integrating it into the host genome. The vector exists as a distinct entity that replicates autonomously using the incorporated origins of replication, preventing genomic integration while ensuring stable maintenance through cell divisions
Solution Approach 2:
The vector is replicated as an episome using viral origins of replication (SV40 and EBV) that are recognized by cellular replication machinery. This copying mechanism allows the vector to be duplicated and distributed to daughter cells without requiring integration into host chromosomal DNA, thereby maintaining cellular phenotype while achieving stable vector propagation
3Device complexity
If a single episomal origin of replication is used, then the vector structure remains simple, but the vector is limited to specific cell lines expressing the required trans-acting factor
Solution Approach 1:
The patent creates a universal episomal vector backbone that can function in multiple cell lines by incorporating both SV40 and EBV origins of replication. This single vector design replaces the need for multiple cell-line-specific vectors, allowing one vector to serve multiple functions across different mammalian cell types expressing either SV40 TAg or EBNA-1
Solution Approach 2:
The vector combines elements from two different viral systems (SV40 origin and EBV origin) into a composite episomal vector. This composite structure integrates functional elements from both viral origins, creating a hybrid vector that can be maintained and replicated in cell lines expressing either SV40 TAg or EBNA-1 transcription factors
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention features nucleic acids for recombinant protein expression in mammalian cell culture. The episomal vectors of the invention promote high protein production in mammalian cells expressing the SV40 T Ag or Epstein-Barr virus nuclear antigen (e.g., COS7 or HEK293-6E cells). The methods and systems are useful, for example, in pharmaceutical drug development and cloning, especially for the production of antibodies.